These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20213647)

  • 61. Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
    Eder JP; Chan V; Wong J; Wong YW; Ara G; Northey D; Rizvi N; Teicher BA
    Cancer Chemother Pharmacol; 1998; 42(4):327-35. PubMed ID: 9744779
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
    Desai SD; Zhang H; Rodriguez-Bauman A; Yang JM; Wu X; Gounder MK; Rubin EH; Liu LF
    Mol Cell Biol; 2003 Apr; 23(7):2341-50. PubMed ID: 12640119
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of topoisomerase I/DNA complexes in patients administered topotecan.
    Subramanian D; Kraut E; Staubus A; Young DC; Muller MT
    Cancer Res; 1995 May; 55(10):2097-103. PubMed ID: 7743509
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product.
    Kokoshka JM; Capson TL; Holden JA; Ireland CM; Barrows LR
    Anticancer Drugs; 1996 Sep; 7(7):758-65. PubMed ID: 8949987
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy.
    Cragg GM; Newman DJ
    J Nat Prod; 2004 Feb; 67(2):232-44. PubMed ID: 14987065
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
    J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats.
    Kase Y; Hayakawa T; Togashi Y; Kamataki T
    Jpn J Pharmacol; 1997 Dec; 75(4):399-405. PubMed ID: 9469646
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Irinotecan pharmacokinetics].
    Chabot GG; Robert J; Lokiec F; Canal P
    Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synergistic effects of irinotecan and flavonoids on Ehrlich ascites tumour-bearing mice.
    Knežević AH; Dikić D; Lisičić D; Kopjar N; Oršolić N; Karabeg S; Benković V
    Basic Clin Pharmacol Toxicol; 2011 Nov; 109(5):343-9. PubMed ID: 21624058
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cellular resistance to camptothecins.
    Pommier Y; Gupta M; Valenti M; Nieves-Neira W
    Ann N Y Acad Sci; 1996 Dec; 803():60-73. PubMed ID: 8993501
    [No Abstract]   [Full Text] [Related]  

  • 75. Irinotecan and Δ⁸-Tetrahydrocannabinol Interactions in Rat Liver: A Preliminary Evaluation Using Biochemical and Genotoxicity Markers.
    Lucić Vrdoljak A; Fuchs N; Mikolić A; Žunec S; Brčić Karačonji I; Jurič A; Prester L; Micek V; Neuberg M; Čanović S; Mršić G; Kopjar N
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29865166
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.
    Shin WS; Han J; Kumar R; Lee GG; Sessler JL; Kim JH; Kim JS
    Sci Rep; 2016 Jul; 6():29018. PubMed ID: 27374023
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source.
    Zhou BN; Hoch JM; Johnson RK; Mattern MR; Eng WK; Ma J; Hecht SM; Newman DJ; Kingston DG
    J Nat Prod; 2000 Sep; 63(9):1273-6. PubMed ID: 11000035
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage.
    Sun M; Duann P; Lin CT; Zhang H; Liu LF
    Ann N Y Acad Sci; 2000; 922():340-2. PubMed ID: 11193917
    [No Abstract]   [Full Text] [Related]  

  • 79. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors.
    Kohn KW; Pommier Y
    Ann N Y Acad Sci; 2000; 922():11-26. PubMed ID: 11193886
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immobilizing topoisomerase I on a surface plasmon resonance biosensor chip to screen for inhibitors.
    Tsai HP; Lin LW; Lai ZY; Wu JY; Chen CE; Hwang J; Chen CS; Lin CM
    J Biomed Sci; 2010 Jun; 17(1):49. PubMed ID: 20565729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.